Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Faroux

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Frontiers in Oncology|July 2, 2021
High-Density of FcγRIIIA<sup>+</sup> (CD16<sup>+</sup>) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A AxisMarie Denis Musquer, Nicolas Jouand, Morgane Pere, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2014
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308Pierre Michel, Gilles Breysacher, Françoise Mornex, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 2, 2021
First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre studyClaire Gallois, Emilie Hafliger, Edouard Auclin, et al.
Clinical Colorectal Cancer|January 12, 2016
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal CancerAlexandra Lapeyre-Prost, Marine Hug de Larauze, Benoist Chibaudel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2019
Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: <i>Post hoc</i> Analysis of the MOSAIC and PETACC-8 TrialsEdouard Auclin, Julien Taieb, Come Lepage, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
The American Journal of Gastroenterology|July 9, 2014
Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter studyGilles Macaigne, Pierre Lahmek, Christophe Locher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.
Therapeutic Advances in Medical Oncology|January 5, 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trialBernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Frontiers in Oncology|July 2, 2021
High-Density of FcγRIIIA<sup>+</sup> (CD16<sup>+</sup>) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A AxisMarie Denis Musquer, Nicolas Jouand, Morgane Pere, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2014
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308Pierre Michel, Gilles Breysacher, Françoise Mornex, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|September 2, 2021
First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre studyClaire Gallois, Emilie Hafliger, Edouard Auclin, et al.
Clinical Colorectal Cancer|January 12, 2016
Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal CancerAlexandra Lapeyre-Prost, Marine Hug de Larauze, Benoist Chibaudel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 3, 2019
Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: <i>Post hoc</i> Analysis of the MOSAIC and PETACC-8 TrialsEdouard Auclin, Julien Taieb, Come Lepage, et al.
Cancers|April 27, 2024
First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA)Jean-Louis Legoux, Roger Faroux, Nicolas Barrière, et al.
The American Journal of Gastroenterology|July 9, 2014
Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter studyGilles Macaigne, Pierre Lahmek, Christophe Locher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2018
Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9)Thomas Aparicio, Francois Ghiringhelli, Valérie Boige, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 4, 2020
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II studyViolaine Randrian, Antoine Adenis, Jérôme Desrame, et al.
Therapeutic Advances in Medical Oncology|January 5, 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trialBernadette de Rauglaudre, Camille Sibertin-Blanc, Aurélie Fabre, et al.
Pageof 5